New insider activity at Diamedica Therapeutics ( (DMAC) ) has taken place on September 4, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Jan Stahlberg has made a substantial investment in Diamedica Therapeutics by purchasing 1,000,000 shares, valued at $5,951,086.
Recent Updates on DMAC stock
In the last 24 hours, DiaMedica Therapeutics has experienced significant developments impacting its stock. The company reported promising interim results from its Phase II trial of DM199 for preeclampsia, showing a statistically significant reduction in blood pressure, which could enhance the treatment’s perceived efficacy and safety. Additionally, DiaMedica completed a $30 million private placement, extending its financial runway into 2027, and entered into a $100 million sales agreement with TD Securities, potentially bolstering its financial position further. These financial maneuvers are crucial as the company faces increased net losses and rising operational costs. The inclusion in the Russell 2000 and 3000 indexes and the appointment of Dr. Julie Krop as Chief Medical Officer are strategic moves to enhance visibility and expertise. These developments, alongside ongoing advancements in their clinical trials, particularly in stroke and preeclampsia programs, have influenced the stock’s outlook, despite the financial challenges and speculative valuation due to the absence of earnings.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
YTD Price Performance: -3.81%
Average Trading Volume: 342,200
Technical Sentiment Signal: Buy
Current Market Cap: $275M